Department of Vascular Surgery and Kidney Transplantation, University Hospital of Strasbourg, Strasbourg, France.
Department of Radiology, University Hospital of Strasbourg, Strasbourg, France.
J Endovasc Ther. 2022 Dec;29(6):885-892. doi: 10.1177/15266028211067727. Epub 2022 Jan 11.
The purpose of this study was to evaluate the efficacy of polycystic kidney embolization, performed to reduce kidney volume before heterotopic kidney transplantation, as this technique could be an alternative to pretransplant nephrectomy.
All patients who underwent pretransplant embolization of polycystic kidneys were included in a prospective register from June 2014 to February 2020. All patients underwent computed tomography (CT) scan with volumetric reconstruction (OsiriX, Bernex, Switzerland) before embolization and were then followed up at 3 and 6 months after embolization. Primary outcome was percentage of kidney volume reduction. Secondary outcomes were 30 day mortality and morbidity.
Thirty-one embolizations performed on 29 patients (medium age = 55.6; 62.1% male) were included between June 2014 and February 2020. All patients were under dialysis before embolization (9 peritoneal dialysis and 20 hemodialysis). Technical success was observed in 96.8% of cases. Mean procedural time was 65 minutes (range = 35-106 minutes) and mean length of in-hospital stay was 3.8 days (range = 3-6 days). A volume reduction allowing a kidney transplant was obtained for 28 patients (96.5%). The mean volume reduction was 39.9% (range = 6.01-68.2). The main observed complication was postembolization pain in 10 cases (32.2%). One patient needed complementary nephrectomy due to insufficient volume reduction. Twenty-three patients (79.3%) received renal transplant during follow-up with a mean delay of 19.5 month (range = 4-54).
Polycystic kidney embolization is an effective and safe minimally invasive technique. It can be proposed as the first-choice technique for kidney transplant recipients as an alternative to pretransplantation nephrectomy.
本研究的目的是评估多囊肾栓塞术的疗效,该技术可用于减少异体肾移植前的肾脏体积,作为移植前肾切除术的替代方法。
自 2014 年 6 月至 2020 年 2 月,所有接受多囊肾移植前栓塞术的患者均被纳入前瞻性登记。所有患者在栓塞术前均行 CT 扫描(OsiriX,瑞士 Bernex),并在栓塞后 3 个月和 6 个月进行随访。主要结果是肾脏体积减少的百分比。次要结果是 30 天死亡率和发病率。
2014 年 6 月至 2020 年 2 月,共对 29 例患者的 31 次栓塞术进行了研究。所有患者在栓塞前均接受透析(9 例腹膜透析,20 例血液透析)。技术成功率为 96.8%。平均手术时间为 65 分钟(范围 35-106 分钟),平均住院时间为 3.8 天(范围 3-6 天)。28 例患者获得了可进行肾移植的肾脏体积缩小(96.5%)。平均体积减少 39.9%(范围 6.01-68.2)。主要观察到的并发症是 10 例(32.2%)栓塞后疼痛。由于体积减少不足,1 例患者需要补充肾切除术。23 例(79.3%)患者在随访期间接受了肾移植,平均延迟 19.5 个月(范围 4-54)。
多囊肾栓塞术是一种有效且安全的微创技术。它可以作为移植前肾切除术的替代方法,作为肾移植受者的首选技术。